Caroline M. Alexander, Ph.D. University of Wisconsin Madison, Wisconsin 53706

Similar documents
TITLE: Mammary Specific Expression of Cre Recombinase Under the Control of an Endogenous MMTV LTR: A Conditional Knock-out System

TITLE: Molecular Determinants Fundamental to Axon Regeneration after SCI

TITLE: Molecular Targeting of the P13K/Akt Pathway to Prevent the Development Hormone Resistant Prostate Cancer

a Award Number: W81XWH TITLE:

TITLE: Alternative RNA Splicing of CSF3R in Promoting Myelodysplastic Syndromes. PRINCIPAL INVESTIGATOR: Seth Corey, MD

TITLE: Induced Pluripotent Stem Cells as Potential Therapeutic Agents in NF1

Charles Shuler, Ph.D. University of Southern California Los Angeles, California Approved for Public Release; Distribution Unlimited

Shunji Morita, M.D. Columbia University New York, New York 10032

TITLE: Epithelin/Granulin Precursor Expression in Human Breast Carcinoma

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Identification of Protein Kinases Required for NF2 Signaling

TITLE: The Roles of the Bone Marrow Microenvironment in Controlling Tumor Dormancy. CONTRACTING ORGANIZATION: Wake Forest School of Medicine

CONTRACTING ORGANIZATION: University of Nebraska Medical Center

TITLE: A Novel Urinary Catheter with Tailorable Bactericidal Behavior. CONTRACTING ORGANIZATION: LONDON HEALTH SCIENCES CENTRE RESEARCH London N6C 2R5

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Boston, MA PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Genomewide Screen for Synthetic Lethal Interactions with Mutant KRAS in Lung Cancer

CONTRACTING ORGANIZATION: Indiana University School of Medicine Indianapolis, IN 46202

TITLE: Androgen Regulation of Human Prostate Cell Growth. PRINCIPAL INVESTIGATOR: Robert W. Harrison, III, M.D.

TITLE: Enhancement of Skeletal Muscle Repair by the Urokinase Type Plasminogen Activator System

CONTRACTING ORGANIZATION: Henry M. Jackson Foundation for the Advancement of Military Medicine Rockville, MD 20852

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Restoration of Wild-Type Activity to Mutant p53 in Prostate Cancer: A Novel Therapeutic Approach

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Approved for Public Release; Distribution Unlimited

CONTRACTING ORGANIZATION: Albert Einstein College of Medicine Bronx, NY 10461

CONTRACTING ORGANIZATION: Indiana University Indianapolis, IN

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Highly specific targeting of the TMPRSS2/ERG fusion gene in prostate cancer using liposomal nanotechnology

AD_. TITLE: Targeted Retroviral Infection of mammary Cells in Viral Receptor Transgenics

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH TITLE: Direct inhibition of Skp2 for the Treatment of Advanced Prostate Cancer. PRINCIPAL INVESTIGATOR: Hyun-Suk Lim

Hanove,r NH PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Preclinical Studies of Induced Pluripotent Stem Cell-Derived Astrocyte Transplantation in ALS

PRINCIPAL INVESTIGATOR: Ann W. Hsing, PhD. CONTRACTING ORGANIZATION: T.R.U.E. Research Foundation San Antonio, TX 78217

Award Number: W81XWH TITLE: Magnetic Resonance Characterization of Axonal Response to Spinal Cord Injury

TITLE: Antineoplastic Efficacy of Novel Polyamine Analogues in Human Breast Cancer.

TITLE: Engineering Anti-EGFR Antibodies for Treatment of Breast Cancers with Poor Prognosis

University of Florida Gainesville, FL PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Exploring Neurofibromin Function in a Yeast Model of NF1. CONTRACTING ORGANIZATION: University of Pennsylvania Philadelphia, PA 19104

CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor, MI,

TITLE: Engineering Anti-EGFR Antibodies for Treatment of Breast Cancers with Poor Prognosis

TITLE: Identification of Prostate Cancer Metastasis-Suppressor Genes Using Genomic shrna Libraries

TITLE: Development of Targeted Sindbis Virus Vectors for Potential Application to Breast Cancer Therapy

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Elucidating Mechanisms of Farnesyltransferase Inhibitor Action and Resistance in Breast Cancer by Bioluminescence Imaging

TITLE: Cell-penetrating Bispecific Antibodies for Targeting Oncogenic Transcription Factors in Advanced Prostate Cancer

TITLE: A Fusogenic Oncolytic Herpes Simplex Virus for Therapy of Advanced Ovarian Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Characterization of Odin, a Novel Inhibitory Molecule, in EGF Receptor Signaling

Award Number: DAMD Efficient and Rapid Development of Transgenic Hamster Models of TSE's Using a Radical New Technology TITLE:

CONTRACTING ORGANIZATION: The Salk Institute for Biological Studies La Jolla, CA

TITLE: Quantification of Protein Signatures in Archived Human Prostate Tissues Using Shotgun Proteomic Methods

TITLE: Malaria Prevention by New Technology: Vectored Delivery of Antibody Genes

TITLE: Vitamin D and Related Genes, Race, and Prostate Cancer Aggressiveness

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Targeting Amino Acid-mTORC1 Signaling Limb for TSC Suppression

Brenton G. Mar. University of Illinois Champaign, IL Approved for Public Release; Distribution Unlimited

TITLE: Prostate Specific Antigen-Triggered Prodrug of S-Trityl-L-Cysteine, an Eg5 Kinesin Inhibitor and Antimitosis Agent with Low Neurotoxicity

Approved for Public Release; Distribution Unlimited

TITLE: Development of Targeted Sindbis Virus Vectors for Potential^Application to Breast Cancer Therapy

TITLE: Use of Intraductal Adenovins Transduction to Assess the Mammary Tumorigenic Potential of a Constitutively Active Prolactin Receptor

TITLE: Catalytic bioscavengers human butyrylcholinesterase and paraoxonase sequestered to the center for CNS

TITLE: Decreasing Skin Graft Contraction through Topical Wound Bed Preparation with Anti-Inflammatory Agents. Tacoma, WA 98402

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland Approved for public release; distribution unlimited

CONTRACTING ORGANIZATION: University of Washington Seattle, Washington

AD (Leave blank) PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Johns Hopkins University, Baltimore, MD 21205

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Cell-penetrating Bispecific Antibodies for Targeting Oncogenic Transcription Factors in Advanced Prostate Cancer

TITLE: Extended Storage of Pathogen-Reduced Platelet Concentrates (PRECON) Seattle, WA 98104

TITLE: Novel Small-Molecule Inhibitor of Tyk2: Lucrative Therapeutic Target in Lupus

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Eglin Air Force Base Ecological Monitoring Program. CONTRACTING ORGANIZATION: Florida National Area Inventory- Tallahassee, Florida

TITLE: Expression of Endogenous Suppressors of HER2 Overexpression in Breast Cancer

AD (Leave blank) Award Number: W81XWH TITLE: Development of a Hand Held Thromboelastograph. PRINCIPAL INVESTIGATOR: Dr.

Stem Cel s Key Words:

TITLE: Regenerative Medicine and Restoration of Joint Function

TITLE: Role of Hsp90 in Androgen-Refractory Prostate Cancer. CONTRACTING ORGANIZATION: University of Pittsburgh Pittsburgh, PA 15260

TITLE: Structural Characterization of the Interdomain Features of the Estrogen Receptor

TITLE: Phase I Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer

TITLE: Use of GDNF-Releasing Nanofiber Nerve Guide Conduits for the Repair of Conus Medullaris/Cauda Equina Injury in the Nonhuman Primate

ANNOUNCEMENTS. HW2 is due Thursday 2/4 by 12:00 pm. Office hours: Monday 12:50 1:20 (ECCH 134)

TITLE: Targeted Elimination of PCDH-PC Expressing Prostate Cancer Cells for Control of Hormone-Resistant Prostate Cancer

TITLE: Potential Therapeutic Use of Relaxin in Healing Cranial Bone Defects

TITLE: Identification of Androgen Receptor-Regulated Genes in Castration-Recurrent Prostate Cancer

MicroRNAs Modulate Hematopoietic Lineage Differentiation

Northern California Institute for Research and Education Inc. San Francisco, CA

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

REPORT DOCUMENTATION PAGE

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland Distribution Unlimited

CONTRACTING ORGANIZATION: Dana Farber Cancer Institute Boston, MA 02115

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

NEW LIMITATION CHANGE TO Approved for public release, distribution unlimited

Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate toward tumor blood vessels Supplementary Information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: University of Colorado, Denver Aurora, CO REPORT DATE: September 2017

About ATCC. Established partner to global researchers and scientists

Transcription:

AD Award Number: TITLE: Wnt-induced Progenitors: Are They Highly Mutable? PRINCIPAL INVESTIGATOR: Caroline M. Alexander, Ph.D. CONTRACTING ORGANIZATION: University of Wisconsin Madison, Wisconsin 53706 REPORT DATE: September 2004 TYPE OF REPORT: Final PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

Form Approved REPORT DOCUMENTATION PAGE OMB No. 074-0188 pubk reprig burden for it"s oofte ion of klormatlon is estinated to average I hoiur per response, wsuin te fime for reviewing instnjdfions. seardn exting data smirces, gafieig th data needed, and ormptebtig and reviewig tis cotection of tornmation, Send ocnments regardin this burden estimate or any other aspect of this collection of sifoinatin inckidirg suggestons for reducing this burden to Washtgon Headquarters Services, Diectorate for information Operations and Reports, 1215 Jefferson Davis Ihi-,ay. Suite 1204, Arlkton, VA 22202-4302, and to the Offise of and Budg Paperwork Reduction o (0704-0188), Wast on, DC 20503 1. AGENCY USE ONLY 2. REPORT DATE 3. REPORT TYPE AND DATES COVERED (Leave blank) I September 2004 Final (1 Sep 2003-31 Aug 2004 4. TITLE AND SUBTITLE 5. FUNDING NUMBERS Wnt-induced Progenitors: Are They Highly Mutable? ) 6. AUTHOR(S) Caroline M. Alexander, Ph.D. 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION University of Wisconsin REPORT NUMBER Madison, Wisconsin 53706 E-Mail: 9. SPONSORING I MONITORING 10. SPONSORING I MONITORING AGENCY NAME(S) AND ADDRESS(ES) AGENCY REPORT NUMBER U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION I AVAILABILITY STATEMENT 12b. DISTRIBUTION CODE Approved for Public Release; Distribution Unlimited 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) Dysregulated Wnt signaling is the cause of many human tumors, and induces breast cancer in mice. We have previously found that the initiating response to Wnt signaling is the accumulation of breast somatic stem cells. We propose that tumor development is related to this increase, and sought with this proposal to test whether the stem cells that arise in transgenic mice expressing Wnt effectors are more mutable than usual. This would explain why the preneoplastic glands invariably acquire mutagenic changes and progress to tumor development. In order to test this hypothesis, we cultured mammary clonagens (mammospheres) and proposed to test their mutability with chemical carcinogens. We found that, contrary to our prediction, mammospheres are almost completely absent in cultures of mammary epithelial cells that express Wnt effectors. Similarly, adherent clonagen numbers were reduced by 90%. We anticipated that their number would increase by 10-fold to reflect other results. We are investigating this phenomenon to determine whether this is due to inhibition of clonagen differentiation and expansion by ectopic Wnt signaling. This is likely to enable us to describe better the selective effects of Wnt signaling on mammary stem cells. 14. SUBJECT TERMS 15. NUMBER OF PAGES genomic instability, oncogenes, cancer-related biology, endogenous 7 factors 16. PRICE CODE 17. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 20. UMITATION OF ABSTRACT OF REPORT OF THIS PAGE OF ABSTRACT Unclassified Unclassified Unclassified Unlimited NSN 7540-01-280-5500 Standard Form 298 (Rev. 2-89) Pirecfibed by ANS Std. Z361S 236.102

Table of Contents Cover... 1 SF 298... 2 Table of Contents... 3 Introduction... 4 Body... 4 Key Research Accomplishments... 6 Reportable Outcomes... 6 Conclusions... 7 References... 7 Appendices... NA 3

Concept A ward DAMD1 7-03-1-0 739 9/1/03-8/31/04 Wnt-induced Progenitors: Are they Highly Mutable? Introduction Ectopic Wnt signaling is highly tumorigenic for mammalian epithelia. We have previously found that Wnt effectors induce mouse mammary stem cells to accumulate, and that this is closely correlated with the risk of subsequent tumor development (Liu et al., 2004). These somatic stem cells are a likely source of tumor precursor cells; they have the longevity that is required to fix and accumulate the genetic changes that confer a growth advantage on preneoplastic cells. In an effort to describe why increased stem cell number leads to tumor development, we proposed to test whether Wnt-induced mammary stem cells were more mutable than normal stem cells. In order to do this, we aimed to transfer normal and Wnt-induced mammary epithelial cell populations to suspension culture, to treat them with mutagenic carcinogens and to evaluate the fraction of mutant mammospheres (clonagens) that developed. Our hypothesis was that Wnt effectors change the predominant type of stem cell division from asymmetric self-renewal (associated with little genomic risk) to one that creates a population of long-lived but highly mutable stem cells that are likely to acquire oncogenic mutations. Body (Research Accomplishments) Mammospheres that develop from mammary epithelial cell (MEC) populations at clonagenic frequencies may be analogous to the development of neurospheres in suspension culture of neural tissue. Neurospheres have stem cell activity in vivo and can be serially propagated for long periods. After dissociation of primary MECs from normal breast tissue, single cells form round clusters (consisting of -150-300 cells) after 7-10 days of culturing, with a frequency of one sphere per 2,000 cells (Dontu et al., 2003). We found that the number of mammospheres that develop in Wnt-induced mammary epithelial populations was reduced by 90%. This was surprising to us because we have already established that the stem cell activity of these populations is increased in vivo (using fat pad transfer) and that a subpopulation enriched in stem cells (SP fraction) is also increased (in ANlcat MECs by a factor of 15). This result did preclude us from measuring mutation rates as proposed, but has led us instead to evaluate why this happened, and to test key properties of mammosphere clonagens. We cultured mammospheres from mammary epithelial cells (MECs) prepared from mammary glands from our two Wnt effector strains, [MMTV-Wntl] and [MMTV-ANl3catenin] (ANo3cat) transgenic mice (and from non-transgenic controls). The frequency of establishment of mammary clonagens from normal glands was similar to that published by Dontu et al. (2003). We observed that the number of mammospheres that formed from transgenic glands from Wnt effector strains (the example shown is from MMTV-ANlcatenin glands) was decreased by 90% (Fig. 1). 4

Fig 1. AN/Icat-expressing MECs form mammospheres less efficiently than do control MECs. MECs were isolated from 2-3-month-old FVB MMTV-ANpcat or control littermate mice, and cells were cultured at different densities (20,000-180,000 cells per 60 mm plate) on non-adhesive plates in serum-free culture). (A) Representative floating spheres grown from control or AN,8cat-expressing cells following I or 2 weeks of culturing are shown. Not many well-rounded spheres were formed from AN/Icat-expressing MECs, but some clusters did form as shown. (B) Quantitations of number of spheres per 10,000 input cells at various initial cell densities are shown. Spheres that are greater than 135pm in diameter were scored after 10 days of culturing; averages and standard deviations were derived from triplicate cultures. (C) Immunoblot analysis is shown for cell lysates from control and AN/Icatexpressing cells prior to or subsequent of mammosphere culturing. AN/3cat was detected by anti-myc antibody, and anti-/3-tubulin antibody was included as loading controls. A B Coto ek Nct1we 3-- Control 0. X1-0" -r C No. of plated MECs C, 2! 0 0 Mammosphere formation depends upon a subtle balance of growth and differentiation to form semi-mature aggregates of >150 cells. We assumed therefore that if this balance was disturbed by the expression of Wnt effectors, that the suspended clonagens could exist but not be able to expand into mammospheres. To test whether this effect was an artifact of the suspension culture conditions, we changed the protocol to culture instead adherent clonagens that have also been related to stem cell activity (Alvi et al., 2002). This culture assay depends upon culture at low density on feeder layers and entirely different culture media, but the result is identical, that the clonagenic activity of Wnt-induced populations is reduced by 90%. We deduce therefore that this result is remarkably robust. 5

DAMD1 7-03-1-0739 Prior to these studies, we anticipated that the clonagenic frequency would increase to reflect the observed increases in stem cell activity. Various other permutations of media and culture conditions (not described in detail here) did not change this result. This was problematic to pursuing our aim of examining the mutation rate of mammospheres in response to ENU. In response, we have developed Rat-2 feeder cells expressing the soluble canonical Wnt signaling inhibitor, dkkl, and aim to test the clonagenic frequency of Wnt-1-expressing mecs. We reason that if Wnt-signaling is suppressing the ability of clonagens to grow out and differentiate (maintaining them instead as stem cells with little ability to survive in these media), then we will reveal the clonagenic activity on these feeder cells. These experiments are ongoing. The premise of these studies is that the clonagens that expand into mammospheres are related to mammary stem cells. Mammospheres can be serially propagated, are enriched in SP progenitor fractions and give rise to both mammary lineages in culture (Dontu et al., 2003). However, given the paradoxical results we have obtained, we sought to validate the stem cell activity of mammospheres by transplantation back to fat pads. To date, we have not been successful. Another group has reported successful repopulation of fat pads using a mammosphere inoculum (Kurpioz and Hassell, personal communication), but their results suggest that the stem cell potency of these structures is low and incomplete. We continue to work on developing culture conditions that will give mammary stem biologists the same power as the Dexter cultures give to hematopoietic stem cell biologists. This is key to the functional evaluation of stem cell activity. Key Research Accomplishments "* We have found that mammosphere formation is almost totally inhibited in MEC populations that express either a soluble or intracellular Wnt effector transgene. "* This result is also true for mammary clonagens isolated and cultured by distinct means, and we conclude that the result is highly robust. "* Although this precludes us from testing the mutability of these clonagens, it has led us to test in vivo whether mammosphere formation constitutes a valid assay of stem cell potential. We remain to be convinced that mammospheres retain sufficient stem cell potential to make them a suitable assay criterion. Reportable Outcomes Poster: Keystone meeting; "Stem Cells and Development" January 2004. B.L. Liu, S.S. Khwaja, and C.M. Alexander PhD Thesis: Bob L. Liu, University of Wisconsin-Madison, 2004. Pre-A ward Data: Data will be used in applications to the NIH (Alexander, PI): The role of stem cells in mouse mammary tumor development. 6

Conclusions We continue to analyze the reasons for the paradoxical results we have obtained. Our experiments aim to describe the selective effects of Wnt effectors on growth or survival of progenitor cells, in order to find out why this response is linked to tumor development. References Alvi, A., Clayton, H., Joshi, C., Enver, T., Ashworth, A., Vivanco, M. d. M., Dale, T. C., and Smalley, M. J. (2002). Functional and molecular characterisation of mammary side population cells. Breast Cancer Res. 5, RI-R8. Dontu, G., Abdallah, W. M., Foley, J. M., Jackson, K. W., Clarke, M. F., Kawamura, M. J., and Wicha, M. S. (2003). In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17, 1253-1270. Liu, Y., McDermott, S. P., Khwaja, S. S., and Alexander, C. M. (2004). The transforming ability of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc. Natl. Acad. Sci. USA 101, 4158-4163. 7